The effect of the proinflammatory cytokine interleukin (IL)-1b b on the cellular proliferation of human osteoblastic cells (SaM-1) and osteosarcoma-derived cells (SaOS-2, HOS, and MG-63) was examined. IL-1b b stimulated the proliferation of SaM-1 and MG-63 cells, but had no effect on that of SaOS-2 or HOS cells. Using reverse transcription-polymerase chain reaction (RT-PCR) analysis, the mRNA expression of IL-1 receptor type I (IL-1R1) was detected in SaM-1 and MG-63 cells consistently, but not in SaOS-2 or HOS cells in the proliferative stage. Neither the decoy inhibitory IL-1 receptor type II (IL-1R2) nor IL-1R antagonist mRNA was detected in any of the cell lines, suggesting that IL-1b b stimulated proliferation via IL-1R1. The IL-1b b-stimulated proliferation was inhibited by the MAPK kinase (MEK) inhibitor PD98059 but not by the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580 or the cyclooxygenase-2 specific inhibitor NS-398, suggesting that IL-1b b stimulated proliferation via MEK, without affecting prostaglandin E 2 synthesis. IL-1b b stimulated cellular proliferation but inhibited the synthesis of osteocalcin containing g g-carboxylated glutamic acid (Gla-OSCAL). Both the increased proliferation and decreased Gla-OSCAL synthesis were suppressed by vitamin K 2 (VK 2 ), which is a cofactor for g g-carboxylase. Furthermore, the inhibitory effect of VK 2 on IL-1b b-stimulated proliferation was suppressed by warfarin. However, rifampicin the nuclear receptor steroid and xenobiotic receptor (SXR) ligand had no effect of IL-b b, suggesting that IL-1b b is involved in VK 2 dependent g g-calboxylation but not SXR-activation. These results suggest that IL-1b b stimulated cellular proliferation via MEK and inhibited Gla-OSCAL synthesis, which were both inhibited by VK 2 via g g-carboxylation.
Interleukin (IL)-1b is a multiple proinflammatory cytokine that regulates various cellular and tissue functions. In bone tissue, IL-1b is a potent cytokine for bone resorption and participates in multiple steps of osteoclast recruitment such as differentiation, multinucleation, activation, and survival. [2] [3] [4] [5] On the other hand, the cytokines involved in osteoblastic activity have been poorly characterized, and little effort has been made to use suitable osteoblastic cell line to evaluate the effects of IL-1b on cellular proliferation and differentiation. In studies on cytokine-induced proliferation, primary human osteoblasts or osteosarcoma cell lines are used (except for SaOS-2 cells). 6, 7) IL-1b has also been demonstrated to stimulate the proliferation of HOS osteosarcoma cells poorly, 8) suggesting that the population of human osteoblasts comprises both IL-1b-responsive-and nonresponsive cells. To evaluate the response of osteoblastic cells to cytokines, it is necessary to analyze their cellular properties, such as their expression of receptors at each cellular stage examined.
IL-1b inhibits the stimulation of osteocalcin (OSCAL, a marker of the osteoblastic phenotype) synthesis by MG-63 in response to 1,25(OH) 2 D 3 . OSCAL, a vitamin K 2 (VK 2 )-dependent protein in bone, is specifically produced in osteoblasts. 9) OSCAL contains g-carboxy-glutamic acid (Gla-OSCAL), which is synthesized by VK 2 -dependent g-carboxylase. Gla-OSCAL is primarily deposited in the extracellular matrix of bone, where it plays an important role in mineralization by osteoblasts. 10) Although, in rat osteoblastic cells, IL-1b was reported to inhibit OSCAL synthesis and has no influence on proliferation, 6) it stimulates cellular proliferation and inhibits OSCAL synthesis in MG-63 cells. 11) OSCAL expression increases significantly following the postproliferative onset of osteoblast differentiation. This evidence suggests that decreases in Gla-OSCAL (OSCAL containing g-carboxy-glutamic acid) synthesis stimulate proliferation of human osteoblasts.
VK 2 is a co-factor for g-carboxylase, which converts glutamic acid residues into g-carboxy-glutamic acid residues in osteocalcin. VK 2 also has a significant therapeutic effect on involutional osteoporosis. VK 2 modulates the proliferation and function of osteoblastic cells 12) and enhances osteocalcin accumulation in the extracellular matrix of osteoblasts. 13) Recently, it has been reported that menaquinone-7, a VK 2 analogue, regulates osteoblastic differentiation, but not proliferation in mouse osteoblastic MC3T3-E1 cells. 14) Although VK 2 regulation of bone homeostasis has been reported to be mediated by the steroid and xenobiotic receptor SXR, 15) it remains to be elucidated whether the g-carboxylation or SXR system are involved in IL-1b-stimulated proliferation of human osteoblasts.
This study was conducted to compare the effects of IL-1b on cellular proliferation of human osteoblastic cells (SaM-1) and osteosarcoma-derived cells (SaOS-2, HOS, and MG-63). Using suitable osteoblastic cells for evaluating cellular proliferation, we confirmed the signaling pathway leading to IL1b-stimulated proliferation and also investigated whether gcarboxylation was involved in IL-1b-stimulated proliferation in SaM-1 cells. The present results underline the importance of down-regulation of the g-carboxylation of osteocalcin in IL-1b-stimulated cellular proliferation.
MATERIALS AND METHODS
Materials SaM-1 human osteoblastic cells kindly provided by Dr. Koshihara (Tokyo Metropolitan Institute of Gerontology) were used in this study. They were obtained from an explant of the ulnar periosteum taken from a 20-year-old male patient who underwent curative surgery and gave his informed consent for its experimental use. SaM-1 cells have a mitotic life span of 34 population doubling levels (PDL), 16) and we used them at 23-24 PDL in our experiments. HOS and SaOS-2 human osteogenic sarcoma cells were obtained from the RIKEN Cell Bank (Tsukuba, Japan). MG-63 human osteogenic sarcoma cells were from the American Type Culture Collection (Rockville, MD, U.S.A.). Alpha-modified minimum essential medium (a-MEM) was purchased from Gibco BRL (Grand Island, NY, U.S.A.), and fetal calf serum (FCS) was acquired from Cell Culture Laboratories (Cleveland, OH, U.S.A.) and Irvine Scientific (Santa Ana, California, U.S.A.). Recombinant human IL-1b was obtained from PeproTech EC LTD. (London, U.K.), and the 5-bromo-2Ј-deoxyuridine (BrdU) cell proliferation ELISA kit was from Roche (Penzberg, Germany). QIAzol Lysis reagent was obtained from Qiagen (Hilden, Germany). Cell Culture of SaM-1, SaOS-2, HOS, and MG-63 Cells and Analysis of Cellular Proliferation SaM-1 cells were maintained in a-MEM containing 10% FCS and 60 mg/ml kanamycin at 37°C in a humidified atmosphere containing 5% CO 2 in air. Osteosarcoma (SaOS-2, HOS, and MG-63) cells were cultured in a-MEM containing 10% FCS, 100 IU/ml penicillin, and 100 mg/ml streptomycin. For the analysis of proliferation, SaM-1 cells were seeded in 96-well plates at a density of 3ϫ10 3 cells/well and allowed to settle for 24 h, and then the medium was replaced with a-MEM containing 2.5% FCS and IL-1b. All osteosarcomas were seeded in 96-well plates at a density of 1ϫ10 3 cells/well and allowed to settle for 24 h, and then the medium was replaced with a-MEM (serum free) containing IL-1b. After stimulation with IL-1b for 48-55 h, BrdU was added to each well to a final concentration of 10 mM, and the cells were incubated for 1-2 h (SaOS-2, HOS, and MG-63 cells) or overnight (the incubation time with IL-1b was a total of 72 h for the SaM-1 cells). The amount of BrdU-labeled DNA was quantified by ELISA, and the data were expressed as a percentage of the control, which was taken as 100%. For the analysis of gene expression, SaM-1 cells were cultured for 24 h in 10-cm dishes at a density of 3ϫ10 5 cells/dish (proliferative stage), and total RNA was extracted using QIAzol Lysis reagent. The other cell lines were cultured for 24 h in 10-cm dishes at a density of 1ϫ10 5 cells/dish (proliferative stage), and the total RNA was extracted. When the SaM-1 cells were cultured under the above conditions for 4 d, they formed a confluent monolayer (1.5-2ϫ10
6 cells/dish), and the SaOS-2, HOS, and MG-63 cells cultured under the above conditions for 3-4 d did the same (2-4ϫ10 6 cells/dish).
Analysis of mRNA Expression by the Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Total RNA were treated with DNase I (Boehringer Mannheim, GmbH, Germany), and cDNA was synthesized using random primers and Moloney murine leukemia virus reverse transcriptase (Gibco-BRL, Grand Island, NY, U.S.A.), whose synthesis was followed by PCR amplification using synthetic gene primers specific for human IL-1R1, IL-1R2, IL-1R antagonist, 17, 18) and human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a housekeeping gene. 19) The sequences of the synthetic forward and reverse primers for each cDNA and product size are shown in Table 1 . PCR amplification was performed with the GeneAmp PCR System (Perkin Elmer/Cetus, Norwalk, CT, U.S.A.) according to the following settings: denaturation at 95°C for 15 s, annealing at 55°C for 30 s, and elongation at 72°C for 30 s for the appropriate number of cycles. The PCR products were electrophoresed on a 2% Nusive GTG agarose gel (FMC BioProducts, Rockland, ME, U.S.A.), stained with ethidium bromide, and detected with a fluoroimage analyzer (FluorImager 575; Molecular Dynamics, Sunnyvale CA, U.S.A.).
Measurement of OSCAL and Gla-OSCAL Protein The levels of OSCAL and Gla-OSCAL protein in the extracellular matrix were quantified using EIA kits. The cells were treated with IL-1b (5 ng/ml) in the absence or presence of VK 2 (10 mM) for 72 h. Then, the cells and extracellular matrix containing OSCAL, Gla-OSCAL, and collagen, which was produced by osteoblasts, were collected using a cell scraper with PBS and solubilized with 0.1% TritonX-100 solution. The supernatant was measured by EIA. Data are presented as the meanϮS.E.M. of 5 cultures.
Statistical Analysis The statistical significances of differences between the control and treated cells were determined by Student's t-test. The critical value for significance was pϽ0.05. Values are given as meanϮS.E.M.
RESULTS

Effects of IL-1b b on Cellular Proliferation and Gene
Expression of IL-1R1, -1R2, and IL-1R Antagonist mRNA in Human Osteoblastic Cells Although IL-1b (1-10 ng/ml) stimulated the proliferation of SaM-1 and MG-63 cells, it had no effect on that of SaOS-2 or HOS cells (Fig. 1A) . To address the reason for this difference between cell lines, we investigated the expression of IL-1R1, -1R2, and IL-1R antagonist mRNA in the 4 cell lines in the proliferative stage by RT-PCR analysis. As shown in Fig. 1B , the mRNA expression of IL-1R1 was detected in SaM-1 and MG-63 cells consistently, but not in SaOS-2 or HOS cells in 40 cycles, suggesting that the IL-1b-responsive cell line showed a comparatively high level of IL-1R1 mRNA expression in the proliferative stage. Neither IL-1R2 nor IL-1R antagonist mRNA was detected in the proliferative stage in any of the cell lines (Fig. 1B) .
Effects of IL-1b b on Cellular Proliferation in Osteoblastic Cells Treated with or without Mitrogen Activated Protein Kinase (MAPK) Inhibitors or COX-2 Inhibitor MAPK are involved in proliferation, differentiation, and apoptosis. Presently, we investigated whether the MAPK system is involved in the above mentioned IL-1b-stimulated signaling pathway. Figure 2 shows that IL-1b (5 ng/ml)-stimulated proliferation was inhibited by the MEK inhibitor PD98059 (5 mM), but not by the p38 MAPK inhibitor SB203580 (5 mM). Next, we examined the involvement of PGE 2 in the action of IL-1b on proliferation in SaM-1 cells. As shown in Fig. 2 , IL-1b-stimulated proliferation was not inhibited by the cyclooxygenase-2 specific inhibitor NS-398 (1 mM). These results suggest that IL-1b stimulated proliferation via MEK, without involving PGE 2 synthesis or p38MAPK in osteoblasts.
Effects of VK 2 on Gla-OSCAL Synthesis in and Cellular Proliferation of SaM-1 Cells In the present study, the mRNA expression of OSCAL (an osteoblastic phenotypic marker) was detected in all cell lines. Figure 3A shows that treatment with IL-1b for 48 h caused a decrease in the expression of OSCAL mRNA in SaM-1 and MG-63 cells, but similar treatment had no effect on the expression of OSCAL mRNA in SaOS-2 or HOS cells. Under our experimental conditions, OSCAL synthesis was not detected by EIA (data not shown), and so we investigated whether IL-1b increased the synthesis of Gla-OSCAL, which converts the glutamic acid (Glu) residues in OSCAL into g-carboxyglutamic acid (Gla) residues via g-carboxylase. Gla-OSCAL was not detected in the conditioned media, but was detected in the extracellular matrix in osteoblasts. Figure 3B shows the attenuation of Gla-OSCAL synthesis in SaM-1 cells treated with IL-1b (5 ng/ml) for 72 h. No attenuation of Gla-OSCAL synthesis was observed in the presence of VK 2 (10 mM), which is a cofactor for g-carboxylase and increases Gla-OSCAL synthesis. To investigate the relationship between the decrease in the VK 2 -dependent g-carboxylation system and cellular proliferation, the effects of IL-1b on cellular proliferation were examined in SaM-1 cells in the presence of VK 2 . As shown in Fig. 3C , no IL-1b-stimulated proliferation of SaM-1 cells was observed in the presence of VK 2 (10 mM), suggesting that IL-1b stimulated proliferation might be associated with the down-regulation of the g-carboxylation of OSCAL in osteoblastic cells.
Effects of Warfarin and Rifampicin on the Cellular Proliferation of SaM-1 Cells To elucidate whether the VK 2 -dependent g-carboxylation system is involved in IL-1b-stimulated proliferation, we examined the influence of warfarin on the effects of VK 2 on the IL-1b-stimulated proliferation of SaM-1 cells. As shown in Fig. 4A , no inhibitory effect of VK 2 (10 mM) on IL-1b (5 ng/ml)-stimulated proliferation of SaM-1 cells was observed in the presence of warfarin (10 mM). Figure 4B shows that the effect of IL-1b (5 ng/ml) was not influenced by the presence of the known SXR ligand rifampicin (20 mM), suggesting that IL-1b is involved in VK 2 dependent g-calboxylation but not SXR-activation.
DISCUSSION
In the present study, we found that IL-1b significantly stimulated proliferation in SaM-1 and MG-63 cells, but had no effect in SaOS-2 or HOS cells. Both SaM-1 and MG-63 cells showed constitutive mRNA expression of IL-1R1 (the type I receptor mediates cellular responses to IL-1 and binds equally well to IL-1 agonists and antagonists), but no IL-1R2 (the type II, or decoy receptor, preferentially binds to IL-1 agonists over antagonists but does not elicit intracellular signaling 20) ), or IL-1R antagonist (a naturally occurring inhibitor that counterbalances the biological activity of IL-1b by competitive binding to IL-1R 21) ) was detected by RT-PCR analysis. Although both IL-1R1 and IL-1R2 mRNA are expressed in human osteoclast-like cells, 22) the present study demonstrated that the IL-1b-responsive osteoblastic cell lines (SaM-1 and MG-63) expressed a comparatively high level of IL-1R1 mRNA but not IL-1R2 or IL-1R antagonist mRNA in the proliferative stage, suggesting that IL-1b stimulates proliferation via IL-1R1, and that the effect of IL-1b on proliferation was not masked by IL-1R2 or IL-1R antagonist. This is the first report indicating the existence of IL-1b-responsive and -nonresponsive cell lines and that the expression of IL-1R1 mRNA is comparatively high in IL-1b-responsive cell lines in the proliferative stage.
Mitogen-activated protein kinase (MAPK) is an important mediator of intracellular signaling. While generally, MEK is an important mediator of cellular proliferation, p38 MAPK is a key molecule in apoptosis and the response to stress. [23] [24] [25] Although IL-1b stimulates proliferation via the activation of MEK in airway smooth muscle and lung adenocarcinoma cells, 26, 27) it is not clear whether it is involved in the signaling of IL-1b-stimulated proliferation in human osteoblasts. In addition, it has been reported that PGE 2 as well as IL-1b stimulate proliferation 28, 29) and that IL-1b stimulates PGE 2 synthesis 27, 30, 31) in osteoblasts. We investigated the effects of this proinflammatory mediator on proliferation in SaM-1 cells. In the present study, IL-1b-stimulated proliferation was inhibited by an MEK inhibitor, but not by a MAPK inhibitor or a cyclooxygenase-2 inhibitor in SaM-1 cells, indicating that IL-1b-responsive osteoblastic cell lines expressed a high level of IL-1R1 mRNA in the proliferative stage and that IL1b stimulates cellular proliferation via MEK, but not via the activation of p38 MAPK or PGE 2 synthesis.
In the present study, we also observed that IL-1b-stimulated proliferation was accompanied by decreases in the synthesis of OSCAL, which is immediately g-carboxylated and exists as Gla-OSCAL in the extracellular matrix. Whereas IL-1b and TNF-a inhibit OSCAL synthesis and increase DNA synthesis in osteosarcoma MG-63 cells, 6) our current data showed that IL-1b alone inhibited Gla-OSCAL synthesis in the extracellular matrix and increased the proliferation of human osteoblasts. Furthermore, these effects of IL-1b were inhibited by exogenous treatment with VK 2 . One of the major functions of VK is the posttranslational modification of VK-dependent proteins containing g-carboxyglutamic acid (Gla) residues. In VK-dependent carboxylation reactions, the reduced form of VK de-protonates glutamate via gglutamyl carboxylase, and the reduced VK is converted to VK epoxide. In this study, IL-1b-stimulated proliferation was inhibited by VK 2 (10 mM), and the inhibition by VK 2 was not observed in the presence of warfarin, a known inhibitor of gcarboxylation. The evidence presented in this paper suggests that the down-regulation of g-carboxylation is involved in IL-1b-stimulated cellular proliferation in osteoblastic cells. At this time, whether MEK is involved in IL-1b-induced down-regulation of g-carboxylation remains to be shown.
There is currently great interest in the effect of VK 2 on bone metabolism via the steroid and xenobiotic receptor (SXR). SXR, which is an unclear hormone receptor activated by a diverse array of endogenous hormones, dietary steroids, pharmacological agents, and xenobiotic compounds, is expressed in the osteosarcoma cell line MG63 and functions as a mediator of bone homeostasis in addition to its role as a xenobiotic sensor. 15) Tabb et al. also showed that VK 2 also acts as a transcriptional regulator of gene expression in osteosarcoma cells. 15 ) VK 2 binds to and activates SXR and induces expression of the SXR target gene in osteosarcoma cells. VK 2 treatment of osteosarcoma cells increased the mRNA levels of the osteoblast markers bone alkaline phosphatase, osteoprotegerin, osteopontin, and matrix Gla protein. The known SXR activators, rifampicin and hyperforin, induced this panel of bone markers to a similar extent, as did VK 2 . Therefore, we examined the effect of rifampicin on the cellular proliferation of SaM-1 cells treated with or without IL-1b. However, the activator of SXR had no effect on either cell type, suggesting that the SXR-mediated VK 2 signaling network is not involved in the effect on the cellular proliferation of SaM-1 cells.
In conclusion, this is the first report indicating the existence of IL-1b-responsive and -nonresponsive cell lines and that the expression of IL-1R1 mRNA is comparatively high in IL-1b-responsive cell lines in the proliferative stage. IL-1b stimulated cellular proliferation via MEK, but not via p38 MAPK or PGE 2 synthesis. The cytokine stimulated cellular proliferation and inhibited Gla-OSCAL synthesis, which were both inhibited by VK 2 via g-carboxylation. Further research is needed to clarify the relationship between g-carboxylation and cellular proliferation and to provide insights into the mechanism of IL-1b-stimulated proliferation.
